Tenet Healthcare (THC) PT Maintained at $30 at Baird on Enhanced Governance Savings; 'Shares Still Mispriced'

Baird maintained its price target on Tenet Healthcare (NYSE: THC) at $30.00 while maintaining a Outperform rating, following an update to the company's outlook reflecting impact of recent CEO hire.

Analyst White Mayo highlights "swift changes" inside THC, citing new governance enhancements from the new CEO resulting in $250 million in cost saving, coupled with disclosure and accountability, as the analyst suggests THC shares remain significant under appreciated and mispriced.

You May Also Be Interested In

• Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'
• Jefferies Downgrades Enphase Energy (ENPH) to Hold, 'Still Muddling Through'
• Amphenol (APH) PT Raised to $130 at Evercore ISI, Remains Top Pick